Kevin Chow, Ph.D.

Co-Founder, President & Chief Executive Officer

Dr. Chow is a biopharmaceutical professional with 20 years of experience leading business development and licensing in both large and small biopharmaceutical companies. Prior to co-founding Vitaeris and leading negotiations with CSL on Vitaeris’ strategic partnership and purchase option deal, Dr. Chow served as Senior Director and Head of Business Development at Alder Biopharmaceuticals, where he led partnering efforts for Alder’s monoclonal antibody pipeline. Previously, Dr. Chow led pulmonary in-licensing at Gilead Sciences and also helped manage the integration of Corus Pharma after its acquisition by Gilead in 2006. Prior to Gilead, Dr. Chow served as Director of Business Development for Corus Pharma, a specialty pharmaceutical company focused on cystic fibrosis and asthma drug development. From 2000-2003 Dr. Chow served in various business development roles with Diversa Corporation. Dr. Chow holds B.Sc., M.Sc., and Ph.D. degrees in ​Microbiology and Immunology from the University of British Columbia in Vancouver, Canada.

Vitaeris is now part of CSL Behring! We are pleased to become part of CSL Behring, a well-established, global industry leader, and know that the future of clazakizumab is in excellent hands. Together, we have already achieved much progress through our partnership over the past few years and are now in an even stronger position to realize our collective goal of addressing one of the greatest unmet needs in the organ transplant community.

Learn more